

Supplementary Table 2. Clinical features of 19 SLE patients with hematological malignancies

Patient	Sex	Age at SLE diagnosis (y)	Age at HM diagnosis (y)	Latency between HM and SLE (months)	SLEDAI-2K at diagnosis of SLE	SLEDAI-2K at diagnosis of HM	Type of HM (Grade)	Biopsy site to confirm HM	Main treatment to HM	Outcome (To the end of follow-up period)
P1	F	46	46	Synchronously	3	3	AML-M2	Bone marrow	Chemotherapy	Survival
P2	M	27	27	Synchronously	4	4	AML-M2	Bone marrow	Chemotherapy	Not applicable
P3	F	54	54	Synchronously	9	9	MM	Bone marrow	Chemotherapy +ASCT	Survival
P4	F	63	63	Synchronously	10	10	NHL-DLBCL(IV)	Antrum of stomach	Chemotherapy	Dead
P5	M	43	43	Synchronously	4	4	AML-M2	Bone marrow	Chemotherapy	Dead
P6	F	63	63	Synchronously	24	24	HL-Mixed cellularity(IV)	Lymph node	Chemotherapy	Dead
P7	M	75	77	18	4	18	NHL-DLBCL(IV)	Head skull	Chemotherapy	Dead
P8	F	23	24	16	23	18	AML-M3	Bone marrow	Chemotherapy	Survival
P9	F	42	48	75	12	5	NHL-MALT(III)	Parotid gland	Chemotherapy	Survival
P10	F	40	40	Synchronously	4	4	HL-Mixed cellularity(IV)	Lymph node	Chemotherapy	Dead
P11	F	66	66	Synchronously	8	8	MM	Bone marrow	Chemotherapy	Dead
P12	F	55	55	Synchronously	14	14	NHL-TCL(III)	Spleen	Chemotherapy	Survival
P13	F	47	47	7	12	11	NHL-TCL(IV)	Lymph node	Chemotherapy	Dead
P14	F	74	76	52	26	4	NHL-	Lung	Traditional Chinese	Dead

P15	F	52	52	Synchronously	4	4	DLBCL(IV) NHL-	Lymph node	medicine Chemotherapy	Survival
P16	F	25	38	156	-	10	DLBCL(IV) AML-M5	Bone marrow	Chemotherapy	Survival
P17	F	31	48	204	-	0	Plasmacytoma	Bone marrow	Chemotherapy	Dead
P18	F	47	58	132	-	0	NHL-TCL(II)	Neck lump	Chemotherapy	Survival
P19	F	45	48	40	-	7	AML-M2	Bone marrow	Chemotherapy	Dead

* P16-P19 were excluded from baseline analysis because of incomplete data when diagnosed with SLE. Abbreviations: SLE, systemic lupus erythematosus; HM, hematological malignancies; AML, acute myeloid leukemia; NHL, Non-Hodgkin's lymphoma; HL, Hodgkin's lymphoma; DLBCL, diffuse large B-cell lymphoma; TCL, T-cell lymphoma; MALT, mucosa-associated lymphoid tissue; MM, multiple myeloma; ASCT, autologous stem cell transplantation.